EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis

Fiore Casale, Nathan Walters, Aaron Peach, Joanna Dong

Journal of Drugs in Dermatology · 01.12.2023 · 22 (12) · 1160-1165

DOI: 10.36849/jdd.7775 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.11.2023. Verfasst von Fiore Casale und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Porokeratosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Porokeratosis is a group of disorders characterized by aberrant skin keratinization secondary to genetic alterations in the mevalonate pathway, which participates in cholesterol synthesis. While a rare disorder, malignant transformation to squamous cell carcinoma is seen in up to 11% of cases. Recently, topical cholesterol and topical statin therapy have been suggested as a pathogenesis-directed treatment for porokeratosis. METHODS: A PubMed/MEDLINE and Embase literature search was performed using the search terms: "porokeratosis" AND "cholesterol" OR "lovastatin" OR "simvastatin" OR "atorvastatin" OR "fluvastatin" OR "pitavastatin" OR "pravastatin" OR "rosuvastatin" OR "statin." Peer-reviewed clinical trials, case series, and case reports of all porokeratosis subtypes were included. RESULTS: Eleven articles were included in the systematic review and 9 articles in the meta-analysis. The systematic review consisted of an aggregate of 33 patients, most of whom (n=31, 93.9%) applied the treatment twice daily for an average of 9.4 weeks (median=8 weeks), with 93.9% (n=31) experiencing improvement or resolution of porokeratosis. Sixteen patients (48.5%) used lovastatin and 16 (48.5%) used simvastatin with concurrent cholesterol therapy. Mild adverse events including erythema and contact dermatitis were experienced by 12.1% of patients. Our meta-analysis yielded a random effects model supporting a robust reduction in porokeratosis severity (OR = .076, 95% CI [0.022, 0.262]). CONCLUSION: This underpowered meta-analysis provides limited, preliminary evidence supporting the efficacy of topical cholesterol/statin therapy. Overall, quality studies and aggregated sample size are limited; future large clinical trials are needed to further elucidate the role of topical cholesterol/statin therapy in the treatment of porokeratosis. J Drugs Dermatol. 2023;22(12):1160-1165. doi:10.36849/JDD.7775.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsPorokeratosisHumansLovastatinSimvastatinCholesterol

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsLovastatinSimvastatinCholesterol

Zitieren

APA

Casale, F., Walters, N., Peach, A., & Dong, J. (2023). Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis. Journal of Drugs in Dermatology, 22(12), 1160-1165. https://doi.org/10.36849/jdd.7775

Vancouver

Casale F, Walters N, Peach A, Dong J. Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis. Journal of Drugs in Dermatology. 2023;22(12):1160-1165. doi:10.36849/jdd.7775

BibTeX
@article{Casale2023,
  author = {Casale, Fiore and Walters, Nathan and Peach, Aaron and Dong, Joanna},
  title = {Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis},
  journal = {Journal of Drugs in Dermatology},
  year = {2023},
  volume = {22},
  number = {12},
  pages = {1160--1165},
  doi = {10.36849/jdd.7775}
}
Kostenlos starten →